Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes (HECICS) (HECICS)
Intra Operative Bleeding, Blood Salvage
About this trial
This is an interventional other trial for Intra Operative Bleeding, Blood Salvage
Eligibility Criteria
Inclusion Criteria:
Elective cardiac revascularization surgery patients: subgroup analysis for
- on pump coronary artery bypass grafting (CABG)
- off pump CABG (OPCABG)
Exclusion Criteria:
- Urgent procedures
- Severe shock
- Active infection
- Inflammatory diseases
- Active neoplasia
- Immune suppressive drugs
- Active or recent renal replacement therapy (RRT)
- Anticoagulation or anti-aggregation therapy that hasn't been timely interrupted according to guidelines (12,13)
- Need for allogenous blood transfusion before completion of data collection
- Massive peroperative bleeding that cannot be safely managed while collecting study data
Sites / Locations
- Ziekenhuis Oost-Limburg
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
citrate
heparin
A quantity of 20 ml ACD-A per 100 ml of collected blood is used to prevent coagulation in the cell savage process. Pre-prepared ACD-A solutions is available (composition of ACD-A solution used: 22.0 g sodium citrate dehydrate, 24.5 g glucose monohydrate, 8.0 g citric acid monohydrate per 1000 ml of water
A heparinised saline solution of 25,000 IU of heparin per 1 litre of intravenous normal saline (0.9% NaCl) solution is used with a dosage of 20 ml of solution per 100 ml of collected blood. This type of solution is not commercially available and is made locally. This solution is used in the cell salvage process to prevent coagulation.